Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. Recently, trials evaluating a sodium–glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes…

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2ceeon6
via IFTTT